Promise of GPRC5D-targeted CAR-T therapies in multiple myeloma

GPRC5D and FCRH5 Targeted Therapies in MyelomaПодробнее

GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)Подробнее

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMMПодробнее

CAR T-cells in Multiple MyelomaПодробнее

The Promise of Anti-BCMA CAR T-Cell Therapy in MMПодробнее

The promise of CAR-T cells for patients with triple-class exposed myelomaПодробнее

A New Target for CAR-T Therapy in Myeloma - GPRC5D | Fredrik Schjesvold, MD | ASH 2021Подробнее

BMS-986393: GPRC5D-targeted CAR for R/R myelomaПодробнее

BMS-986393, a novel anti-GPRC5D CAR-T cell therapy, in multiple myelomaПодробнее

Beyond BCMA: GPRC5D & FcRH5Подробнее

CAR T Cell Therapy 202Подробнее

The promise of CAR-T therapy for the treatment of AL amyloidosisПодробнее

CAR-T therapy in multiple myeloma: recent updates, clinical trials and future outlooksПодробнее

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее

Challenges associated with the use of off-the-shelf CAR-T products in multiple myelomaПодробнее

A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig HofmeisterПодробнее

An update on the Phase I trial of BMS-986393, a novel GPRC5D-targeted CAR-T, in R/R myelomaПодробнее

The value of CAR-T cell therapy for the treatment of R/R multiple myelomaПодробнее

Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapiesПодробнее